GlassScriptPhysician profile
Robert L Sourk
NPI 1942272554
$32,749.41
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $7,175 · 2021: $2,438 · 2022: $4,447 · 2023: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $464.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $31,153.27 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $234.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.05 | 2019-2020 | |
| Harmony Biosciences LLC | $161.59 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $153.89 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $146.89 | 2019-2020 | |
| Genentech USA, INC. | $124.99 | 2019-2020 | |
| Grifols USA, LLC | $107.88 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $99.44 | 2019-2020 | |
| Glaxosmithkline, LLC. | $90.72 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $57.99 | 2022 | |
| Merck Sharp & Dohme LLC | $56.01 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $43.26 | 2019-2020 | |
| Gilead Sciences, INC. | $29.03 | 2019 | |
| Philips North America LLC | $19.45 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.09 | 2020 | |
| Genzyme Corporation | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sourk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.